New PET tracer aims to spot scarring in organs without a needle
NCT ID NCT07459205
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test a new imaging agent called 68Ga-1A12, which is used in a PET scan to detect fibrosis (scarring) in organs like the lungs. The goal is to see if this scan can diagnose fibrosis earlier and more accurately than current methods, which often require invasive biopsies. The study plans to enroll 50 adults with suspected or confirmed fibrosis-related disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-1A12 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this could provide a non-invasive way to detect and monitor fibrosis earlier and more accurately than current methods.
What could go wrong
This is a small, early-stage study (50 participants) focused on diagnostic accuracy, not treatment. The tracer may not prove reliable enough for widespread use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Daping Hospital
Chongqing, Chongqing Municipality, 400010, China
Contact Phone: •••-•••-•••• Email: •••••@•••••